Review on identification and quantification of genotoxic impurities
Keywords:
Genotoxic, modifying relevant, pharmaceutical ingredientsAbstract
Genotoxic impurities can be broadly defined as those impurities that have been demonstrated to cause harmful changes in genetic material regardless of the mechanism. Globally people suffer from various health complications due to genotoxic impurities. Recent recommendations from European and United States (USA) drug regulatory bodies mandate the management of genotoxic and possibly genotoxic contaminants in pharmaceutical ingredients at per million levels. The purpose of this review is to make a critical analysis of the techniques used to comply with the prevailing rules and regulations and very strict limits on genotoxic impurities. Possible strategies to further expand the scope of currently available technologies and regulations are also to be discussed. These strategies include redesigning the synthesis of the drug substance to avoid introducing problematic impurities; modifying relevant process parameters to eliminate or reduce such impurities to negligible levels; Using process understanding to demonstrate that a particular genotoxic impurity cannot be formed or removed efficiently and by conducting toxicity studies to demonstrate that a suspected impurity is not harmful to it at low levels.
Downloads
References
“Current Good Manufacturing Practice (CGMP) Regulations | FDA.” https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations (accessed Jan. 04, 2022).
“PHARMACEUTICAL CGMPS FOR THE 21 ST CENTURY-A RISK-BASED APPROACH FINAL REPORT,” 2004.
“ICH Expert Working Group: The Value and Benefits... - Google Scholar.” https://scholar.google.com/scholar_lookup?title=The+Value+and+Benefits+of+ICH+to+Drug+Regulatory+Authorities:+Advancing+Harmonization+for+Better+Health&author=ICH+Expert+Working+Group&publication_year=2010 (accessed Jan. 04, 2022).
S. Hall, Rules of thumb for chemical engineers. 2017.
J. V. B.-H. A. I. J. for the P. of and undefined 2014, “Philosophy of science and philosophy of chemistry,” lirias.kuleuven.be, vol. 20, pp. 11–57, 2014, Accessed: Jan. 04, 2022. [Online]. Available: https://lirias.kuleuven.be/1094218?limo=0.
S. Ahuja and K. Alsante, Handbook of isolation and characterization of impurities in pharmaceuticals. 2003.
A. Y. Abdin, P. Yeboah, and C. Jacob, “Chemical Impurities: An Epistemological Riddle with Serious Side Effects,” Int. J. Environ. Res. Public Heal. 2020, Vol. 17, Page 1030, vol. 17, no. 3, p. 1030, Feb. 2020, DOI: 10.3390/IJERPH17031030.
J. P. Bercu, K. L. Dobo, E. Gocke, and T. J. Mcgovern, “Overview of genotoxic impurities in pharmaceutical development,” Int. J. Toxicol., vol. 28, no. 6, pp. 468–478, 2009, doi: 10.1177/1091581809349195.
“Guidance for Industry Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches,” 2008, Accessed: Nov. 28, 2021. [Online]. Available: http://www.fda.gov/cder/guidance/index.htm.
J. I., G. O., S. Adeola, and I. Esiab, “Chemical Carcinogenesis: Risk Factors, Early Detection, and Biomedical Engineering,” Biomed. Sci. Eng. Technol., Jan. 2012, DOI: 10.5772/20209.
K. Nadja, “COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE LIMITS OF GENOTOXIC IMPURITIES GUIDELINE ON THE LIMITS OF GENOTOXIC IMPURITIES,” 2006, Accessed: Nov. 28, 2021. [Online]. Available: http://www.emea.eu.int.
“ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk | European Medicines Agency.” https://www.ema.europa.eu/en/ich-m7-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential (accessed Nov. 28, 2021).
Y. Huang, H. Lu, F. Zhang, and C. Min, “Identification, isolation, characterization, and UHPLC quantification of potential genotoxic impurities in linagliptin,” J. Sep. Sci., vol. 41, no. 21, pp. 3985–3994, Nov. 2018, doi: 10.1002/JSSC.201800623/FORMAT/PDF.
I. G.-Q. (R2), current step, and undefined 2006, “Impurities in new drug products,” triphasepharmasolutions.com, 2006, Accessed: Nov. 28, 2021. [Online]. Available: http://www.triphasepharmasolutions.com/Resources/Q3B(R2) Impurities in New Drug Products.pdf.
I. G.-C. Step and undefined 2005, “Impurities: guideline for residual solvents Q3C (R5),” boroyf.com, 2016, Accessed: Nov. 28, 2021. [Online]. Available: http://www.boroyf.com/Private/Files/20180710/6366682390293144237853981.pdf.
“INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG SUBSTANCES Q3A(R2),” 2006.
S. U. Shah, “Importance of Genotoxicity & S2A guidelines for genotoxicity testing for pharmaceuticals:” IOSR J. Pharm. Biol. Sci., vol. 1, no. 2, pp. 43–54, 2012, doi: 10.9790/3008-0124354.
“ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK M7(R1) Current Step 4 version,” 2017.
R. Holm and D. P. Elder, “Analytical advances in pharmaceutical impurity profiling,” Eur. J. Pharm. Sci., vol. 87, pp. 118–135, May 2016, DOI: 10.1016/J.EJPS.2015.12.007.
A. R. POUNIKAR, M. J. UMEKAR, and K. R. GUPTA, “GENOTOXIC IMPURITIES: AN IMPORTANT REGULATORY ASPECT,” Asian J. Pharm. Clin. Res., pp. 10–25, Jun. 2020, DOI: 10.22159/AJPCR.2020.V13I6.37370.
A. Leistner, S. Haerling, J. D. Kreher, I. Becker, D. Jung, and U. Holzgrabe, “Risk assessment report of potential impurities in cetirizine dihydrochloride,” J. Pharm. Biomed. Anal., vol. 189, Sep. 2020, DOI: 10.1016/J.JPBA.2020.113425.
G. Szekely, M. C. A. De Sousa, M. Gil, F. C. Ferreira, and W. Heggie, “Genotoxic impurities in pharmaceutical manufacturing: Sources, regulations, and mitigation,” Chem. Rev., vol. 115, no. 16, pp. 8182–8229, Aug. 2015, DOI: 10.1021/CR300095F/SUPPL_FILE/CR300095F_SI_001.PDF.
D. I. Robinson, “Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A Review and Perspective,” Org. Process Res. Dev., vol. 14, no. 4, pp. 946–959, Jul. 2010, DOI: 10.1021/OP900341A.
T. Shaikh, “Genotoxic Impurities and Its Risk Assessment in Drug Compounds,” Drug Des. Intellect. Prop. Int. J., vol. 2, no. 4, Oct. 2018, doi: 10.32474/DDIPIJ.2018.02.000143.
" Sugden, Kent D., Christina K. Campo, and Brooke D. Martin. "Direct oxidation of guanine and 7, 8-dihydro-8-oxoguanine in DNA by a high-valent chromium complex: a possible mechanism for chromate genotoxicity." Chemical research in toxicology 14, no. 9 (2001): 1315-1322.
" Chen, Tao, Nan Mei, and Peter P. Fu. "Genotoxicity of pyrrolizidine alkaloids." Journal
of Applied Toxicology: An International Journal 30, no. 3 (2010): 183-196.
" Mei, Nan, Lei Guo, Peter P. Fu, James C. Fuscoe, Yang Luan, and Tao Chen.
"Metabolism, genotoxicity, and carcinogenicity of comfrey." Journal of Toxicology and
Environmental Health, Part B 13, no. 7-8 (2010): 509-526.
“INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS Q3C(R8).”
“COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE 22-23 JUNE 2004 PLENARY MEETING MONTHLY REPORT The Committee for Medicinal Products for Human Use (CHMP) held its 2 nd plenary meeting from,” 2004, Accessed: Jan. 10, 2022. [Online]. Available: http://www.emea.eu.int.
D. Jacobson-Kram and A. Jacobs, “Use of genotoxicity data to support clinical trials or positive genetic findings on a candidate pharmaceutical or impurity . . . . Now what?,” Int. J. Toxicol., vol. 24, no. 3, pp. 129–134, May 2005, DOI: 10.1080/10915810590952933.
Step, “Committee for Human Medicinal Products ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk,” 2015, Accessed: Jan. 10, 2022. [Online]. Available: www.ema.Europa.EU/contact.
G. Szekely, M. C. A. De Sousa, M. Gil, F. C. Ferreira, and W. Heggie, “Genotoxic impurities in pharmaceutical manufacturing: Sources, regulations, and mitigation,” Chem. Rev., vol. 115, no. 16, pp. 8182–8229, 2015, DOI: 10.1021/cr300095f.
T. McGovern and D. Jacobson-Kram, “Regulation of genotoxic and carcinogenic impurities in drug substances and products,” TrAC Trends Anal. Chem., vol. 25, no. 8, pp. 790–795, Sep. 2006, doi: 10.1016/J.TRAC.2006.06.004.
L. Müller et al., “A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess the potential for genotoxicity,” Regul. Toxicol. Pharmacol., vol. 44, no. 3, pp. 198–211, Apr. 2006, doi: 10.1016/J.YRTPH.2005.12.001.
A. R POUNIKAR, M. J UMEKAR, and K. R GUPTA, “GENOTOXIC IMPURITIES: AN IMPORTANT REGULATORY ASPECT,” Asian J. Pharm. Clin. Res., pp. 10–25, Apr. 2020, DOI: 10.22159/AJPCR.2020.V13I6.37370.
“Federal Register :: Draft Guidance for Industry on Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches; Availability.” https://www.federalregister.gov/documents/2008/12/16/E8-29674/draft-guidance-for-industry-on-genotoxic-and-carcinogenic-impurities-in-drug-substances-and-products (accessed Jan. 10, 2022).
D. A. Pierson, B. A. Olsen, D. K. Robbins, K. M. DeVries, and D. L. Varie, “Approaches to Assessment, Testing Decisions, and Analytical Determination of Genotoxic Impurities in Drug Substances,” Org. Process Res. Dev., vol. 13, no. 2, pp. 285–291, Mar. 2008, DOI: 10.1021/OP8002129.
“GENOTOXIC IMPURITIES IN PHARMACEUTICAL PRODUCTS.”
M. Ramble Alegre, F. David, P. Sandra, and G. Vanhoenacker, “Determination of Genotoxic Impurities in Pharmaceuticals,” LCGC Suppl., vol. 31, no. 5, 2013, [Online]. Available: https://www.chromatographyonline.com/view/determination-genotoxic-impurities-pharmaceuticals.
“Residual Solvents Analysis Using GC with Headspace - Quantum Analytics.” https://www.lqa.com/resource/residual-solvents-analysis-using-agilent-intuvo-9000-gc-with-8697-headspace-sampler/ (accessed Jan. 15, 2022).
“Pharmaceutical Impurity Analysis Overview.”
F. David, M. Rambla-Alegre, G. Vanhoenacker, and P. Sandra, “Determination of Genotoxic Impurities in Pharmaceuticals,” LC GC Eur., vol. May 2013, pp. 31–34, May 2013.
A. Teasdale, “Genotoxic impurities : strategies for identification and control,” p. 428, 2010, Accessed: Jan. 15, 2022. [Online]. Available: https://www.wiley.com/en-us/Genotoxic+Impurities%3A+Strategies+for+Identification+and+Control-p-9780470499191.
A. Teasdale et al., “Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control,” Org. Process Res. Dev., vol. 17, no. 2, pp. 221–230, Feb. 2013, DOI: 10.1021/OP300268U.
“Guideline: Q3A (R2), Impurities in New Drug Substances - Google Scholar.” https://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=International+Conference+on+Harmonisation+%28ICH%29&title=Guideline+Q3A+%28R2%29%3A+Impurities+in+New+Drug+Substances (accessed Jan. 28, 2022).
I. G.-Q. (R2), current step, and undefined 2006, “Impurities in new drug products,” triphasepharmasolutions.com, 2006, Accessed: Jan. 28, 2022. [Online]. Available: http://www.triphasepharmasolutions.com/Resources/Q3B(R2) Impurities in New Drug Products.pdf.
I. G.-C. Step and undefined 2005, “Impurities: guideline for residual solvents Q3C (R5),” boroyf.com, 2016, Accessed: Jan. 28, 2022. [Online]. Available: http://www.boroyf.com/Private/Files/20180710/6366682390293144237853981.pdf.
“CHMP: Guideline on the limits of genotoxic impurities, 2006 - Google Scholar.” https://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=EMEA%2FCHMP&title=Guideline+on+the+Limits+of+Genotoxic+Impurities (accessed Jan. 28, 2022).
A. Cartus and D. Schrenk, “Current methods in risk assessment of genotoxic chemicals,” Food Chem. Toxicol., vol. 106, pp. 574–582, Aug. 2017, DOI: 10.1016/J.FCT.2016.09.012.
J. Ashby and R. W. Tennant, “Definitive relationships among chemical structure, carcinogenicity, and mutagenicity for 301 chemicals tested by the U.S. NTP,” Mutat. Res. Genet. Toxicol., vol. 257, no. 3, pp. 229–306, May 1991, DOI: 10.1016/0165-1110(91)90003-E.
C. D. N. Humfrey, “Recent Developments in the Risk Assessment of Potentially Genotoxic Impurities in Pharmaceutical Drug Substances,” Toxicol. Sci., vol. 100, no. 1, pp. 24–28, Nov. 2007, DOI: 10.1093/TOXSCI/KFM173.
“INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE PHARMACEUTICAL DEVELOPMENT Q8(R2),” 2009.
D. Elder and A. Teasdale, “ICH Q9 Quality Risk Management,” ICH Qual. Guidel., pp. 579–610, Sep. 2017, DOI: 10.1002/9781118971147.CH21.
D. I. Robinson, “Control of Genotoxic Impurities in Active Pharmaceutical Ingredients: A Review and Perspective,” Org. Process Res. Dev., vol. 14, no. 4, pp. 946–959, Jul. 2010, DOI: 10.1021/OP900341A.
A. D. Brown et al., “Process Development for Sodelglitazar: A PPAR Panagonist,” Org. Process Res. Dev., vol. 13, no. 2, pp. 297–302, Mar. 2008, DOI: 10.1021/OP8002294.
L. C. Chan, B. G. Cox, and R. S. Sinclair, “Selective hydrolysis of methanesulfonate esters,” Org. Process Res. Dev., vol. 12, no. 2, pp. 213–217, Mar. 2008, DOI: 10.1021/OP700226S/SUPPL_FILE/OP700226S_SI_003.PDF.
G. Szekely, M. C. A. De Sousa, M. Gil, F. C. Ferreira, and W. Heggie, “Genotoxic Impurities in Pharmaceutical Manufacturing: Sources, Regulations, and Mitigation,” Chem. Rev., vol. 115, no. 16, pp. 8182–8229, Aug. 2015, DOI: 10.1021/CR300095F.
Williamson, Elizabeth M. "Drug interactions between herbal and prescription medicines." Drug safety 26, no. 15 (2003): 1075-1092.
(Jordan et al., 2010) Jordan, Scott A., David G. Cunningham, and Robin J. Marles. "Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment." Toxicology and applied pharmacology 243, no. 2 (2010): 198-216.
(Thomas et al., 2001) Thomas, Kate J., J. P. Nicholl, and Patricia Coleman. "Use and expenditure on complementary medicine in England: a population-based survey." Complementary therapies in medicine 9, no. 1 (2001): 2-11.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938
(Kennedy, 2005Kennedy, Jae. "Herb and supplement use in the US adult population." Clinical therapeutics 27, no. 11 (2005): 1847-1858.
Patwardhan et al., 2005Patwardhan, Bhushan, Dnyaneshwar Warude,
PalpuPushpangadan, and Narendra Bhatt. "Ayurveda and traditional Chinese medicine: a comparative overview." Evidence-based complementary and alternative medicine 2, no. 4 (2005): 465-473.);
(Wakdikar, 2004) Wakdikar, Sandhya. "Global health care challenge: Indian experiences and new prescriptions." Electronic Journal of Biotechnology 7, no. 3 (2004): 02-03.
(Atsamo et al., 2011)Atsamo, Albert D., Télesphore B. Nguelefack, Jacques Y. Datté, and
Albert Kamanyi. "Acute and subchronic oral toxicity assessment of the aqueous extract
from the stem bark of Erythrina senegalensis DC (Fabaceae) in rodents." Journal of
Ethnopharmacology 134, no. 3 (2011): 697-702.
Ouedraogo, Moustapha, Thomas Baudoux, Caroline Stévigny, JoëlleNortier, Jean-Marie
Colet, Thomas Efferth, Fan Qu, et al. "Review of current and “omics” methods for
assessing the toxicity (genotoxicity, teratogenicity, and nephrotoxicity) of herbal
medicines and mushrooms." Journal of ethnopharmacology 140, no. 3 (2012): 492-512.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
